Certainly overall survival is the ultimate endpoint, but I would not discount PFS and complete responses (CRs do drive survival benefit in a small subset of patients as evidenced by high dose IL-2). Currently we have no data comparing IO/IO vs IO/TKI combinations head to head, so we generally select...

There isn't necessarily on endpoint that is more important than others. For high burden, symptomatic patients (the minority of patients) then ORR/PFS takes on greater importance. Other populations (eg younger patients with low volume disease) may value longer-term outcomes and the ability to be off ...

In the front-line setting, it is challenging to weigh options because the studies that we have at our disposal have met endpoints from the standpoint of overall survival and response rate. As such, I think we have to look to other measures. I, generally speaking, favor the combination of tyrosine ki...